CHICAGO (PRWEB) NOVEMBER 29, 2019 - Transpara™ 1.6, the leading Artificial Intelligence decision support system for breast cancer screening, that uses deep learning algorithms to automatically detect potential breast cancer in 2D and 3D DBT mammograms, will be unveiled at the Annual Radiological Society of North America (RSNA) meeting, December 1-6, 2019 (ScreenPoint Medical, South Hall #4380).
The software uniquely ranks mammograms on a 10-point scale indicating the short term risk that cancer is present. Independent clinical validations demonstrate that this Transpara Exam Score can reduce workload and help radiologists prioritise patients for further investigation. Interactive decision support is provided to assist radiologists with image interpretation. Studies have shown that Transpara matches the performance of radiologists , thus acting as a ‘second pair of eyes’ which increases diagnostic confidence and accuracy .
Transpara is CE Marked for use with 2D mammography and 3D digital breast tomosynthesis (DBT) images from multiple vendors and is installed at leading breast imaging centers in Europe. Transpara is FDA Cleared for use with 2D mammography in the U.S. and is pending FDA Clearance for use with 3D DBT.
Ad Statistics
Times Displayed: 22374
Times Visited: 452 Stay up to date with the latest training to fix, troubleshoot, and maintain your critical care devices. GE HealthCare offers multiple training formats to empower teams and expand knowledge, saving you time and money
"The showcasing of Transpara 1.6 at RSNA demonstrates our focus on continually improving to ensure we can provide our clients with the best commercially available breast AI," said Nico Karssemeijer, CEO for ScreenPoint Medical. "We understand that reading 3D mammography presents radiologists with huge workload and reading time challenges compared to 2D. With feedback from the field, we redesigned the Transpara 1.6 interface and utilised our patented co-registration slice technology to optimise reading workflow and to ensure peace of mind. Users just click on the region of interest on the synthetic 2D image and are immediately taken directly to the exact slice which saves time.”
“ScreenPoint’s aim is to help radiologists to identify and diagnose breast cancer as early as possible whilst minimizing problems associated with mammography including over-diagnosis. What’s exciting about Transpara 1.6 is that there is now evidence to show that it is catching high grade cancers earlier so that treatment can begin earlier and so improve a woman’s chances of a cure,” said ScreenPoint co-founder, Professor Sir Michael Brady.
Pieter Kroese, COO of ScreenPoint Medical, said: “International interest in the success of the Transpara system has been growing rapidly: Transpara is now being used or piloted in around 20 countries around the world and the feedback from radiologists has been universally positive. We are extremely fortunate to have some excellent partners who have seen at first hand the benefits Transpara can bring to increasingly busy radiologists.”
